Individualized Concurrent Chemotherapy for Patients with Stage III–IVa Nasopharyngeal Carcinoma Receiving Neoadjuvant Chemotherapy Combined with Definitive Intensity-Modulated Radiotherapy
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose This retrospective study aimed to re-evaluate the effect of concurrent chemotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC) in the era of intensity-modulated radiotherapy (IMRT). Materials and Methods A total of 498 patients who received neoadjuvant chemotherapy (NCT) combined with concurrent chemoradiotherapy (CCRT) or IMRT were retrospectively reviewed. The distribution of baseline characteristics was balanced using propensity score matching. Additionally, the results of NCT+IMRT and NCT+CCRT were compared using Kaplan-Meier survival analysis, and differences in survival rates were analyzed using the log rank test. Results There were no significant differences in overall survival (OS), progression-free survival (PFS), distant metastasis-free survival (DMFS), and local progression-free survival (LRFS) between the two groups. Patients were further categorized into risk subgroups based on pretreatment Epstein-Barr virus (EBV) DNA cutoff values using receiver operating characteristic curve analysis. There were no statistically significant differences in OS, PFS, DMFS, and LRFS between patients who received NCT+CCRT and NCT+IMRT in the high-risk group. In the low-risk group, although there were no differences between NCT+CCRT and NCT+IMRT in OS, PFS, and LRFS, patients who received NCT+CCRT had better DMFS than those who received NCT+IMRT. Conclusion Pretreatment EBV DNA level can be used to individualize concurrent chemotherapy for patients with locally advanced NPC. Patients with low pretreatment EBV DNA levels may benefit from concurrent chemotherapy, whereas those with high levels may not. Other treatment modalities need to be explored for high-risk patients to improve their prognosis.
Abstract
Purpose This retrospective study aimed to re-evaluate the effect of concurrent chemotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC) in the era of intensity-modulated radiotherapy (IMRT). Materials and Methods A total of 498 patients who received neoadjuvant chemotherapy (NCT) combined with concurrent chemoradiotherapy (CCRT) or IMRT were retrospectively reviewed. The distribution of baseline characteristics was balanced using propensity score matching. Additionally, the results of NCT+IMRT and NCT+CCRT were compared using Kaplan-Meier survival analysis, and differences in survival rates were analyzed using the log rank test. Results There were no significant differences in overall survival (OS), progression-free survival (PFS), distant metastasis-free survival (DMFS), and local progression-free survival (LRFS) between the two groups. Patients were further categorized into risk subgroups based on pretreatment Epstein-Barr virus (EBV) DNA cutoff values using receiver operating characteristic curve analysis. There were no statistically significant differences in OS, PFS, DMFS, and LRFS between patients who received NCT+CCRT and NCT+IMRT in the high-risk group. In the low-risk group, although there were no differences between NCT+CCRT and NCT+IMRT in OS, PFS, and LRFS, patients who received NCT+CCRT had better DMFS than those who received NCT+IMRT. Conclusion Pretreatment EBV DNA level can be used to individualize concurrent chemotherapy for patients with locally advanced NPC. Patients with low pretreatment EBV DNA levels may benefit from concurrent chemotherapy, whereas those with high levels may not. Other treatment modalities need to be explored for high-risk patients to improve their prognosis.
참고문헌 (28)
- Chen YP, "Nasopharyngeal carcinoma", Lancet, 394, pp.64~80 (2019)
- Chua ML, "Nasopharyngeal carcinoma", Lancet, 387, pp.1012~1024 (2016)
- Ribassin-Majed L, "What is the best treatment of locally advanced nasopharyngeal carcinoma? An individual patient data network meta-analysis", J Clin Oncol, 35, pp.498~505 (2017)
- Chen YP, "Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II-IVA nasopharyngeal carcinoma : CSCO and ASCO guideline", J Clin Oncol, 39, pp.840~859 (2021)
- Sun XS, "The association between the development of radiation therapy, image technology, and chemotherapy, and the survival of patients with nasopharyngeal carcinoma : a cohort study from 1990 to 2012", Int J Radiat Oncol Biol Phys, 105, pp.581~590 (2019)
- Yang Q, "Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma : longterm results of a phase III multicentre randomised controlled trial", Eur J Cancer, 119, pp.87~96 (2019)
- Sun Y, "Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma : a phase 3, multicentre, randomised controlled trial", Lancet Oncol, 17, pp.1509~1520 (2016)
- Zhang Y, "Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma", N Engl J Med, 381, pp.1124~1135 (2019)
- Tang LL, "Effect of radiotherapy alone vs radiotherapy with concurrent chemoradiotherapy on survival without disease relapse in patients with low-risk nasopharyngeal carcinoma : a randomized clinical trial", JAMA, 328, pp.728~736 (2022)
- Wang Q, "Comparison of induction chemotherapy plus concurrent chemoradiotherapy and induction chemotherapy plus radiotherapy in locally advanced nasopharyngeal carcinoma", Oral Oncol, 111, pp.104925~ (2020)
- Lin JC, "Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma", N Engl J Med, 350, pp.2461~2470 (2004)
- Vasudevan HN, "Nasopharyngeal carcinoma and its association with Epstein-Barr virus", Hematol Oncol Clin North Am, 35, pp.963~971 (2021)
- Qu H, "Prognostic value of Epstein-Barr virus DNA level for nasopharyngeal carcinoma : a meta-analysis of 8128 cases", Eur Arch Otorhinolaryngol, 277, pp.9~18 (2020)
- Sun XS, "Individualized concurrent chemotherapy by pretreatment plasma Epstein-Barr viral DNA in II-III stage nasopharyngeal carcinoma : a propensity score matching analysis using a large cohort", Cancer Med, 8, pp.4214~4225 (2019)
- Lin S, "Update report of nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy and hypothesis of the optimal margin", Radiother Oncol, 110, pp.385~389 (2014)
- Lin JC, "Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma : positive effect on overall and progression-free survival", J Clin Oncol, 21, pp.631~637 (2003)
- Wang F, "Influence of concurrent chemotherapy on locoregionally advanced nasopharyngeal carcinoma treated with neoadjuvant chemotherapy plus intensity-modulated radiotherapy : a retrospective matched analysis", Sci Rep, 10, pp.2489~ (2020)
- Li PJ, "Explore the usefulness of concurrent chemotherapy in stage II nasopharyngeal carcinoma : a retrospective study", Front Pharmacol, 12, pp.688528~ (2021)
- Liu L, "Induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus volumetric modulated arc therapy alone in the treatment of stage II-IVB nasopharyngeal carcinoma patients : a retrospective controlled study", Radiat Oncol, 13, pp.148~ (2018)
- Huang CL, "Plasma Epstein-Barr virus DNA load after induction chemotherapy predicts outcome in locoregionally advanced nasopharyngeal carcinoma", Int J Radiat Oncol Biol Phys, 104, pp.355~361 (2019)
- Chen FP, "Circulating Epstein-Barr virus DNA level post induction chemotherapy contributes to prognostication in advanced-stage nasopharyngeal carcinoma", Eur J Cancer, 151, pp.63~71 (2021)
- Xie X, "Molecular prognostic value of circulating Epstein-Barr viral DNA in nasopharyngeal carcinoma : a meta-analysis of 27, 235 cases in the endemic area of southeast Asia", Genet Test Mol Biomarkers, 23, pp.448~459 (2019)
- Zhang AM, "Increased treatment-related mortality with additional cisplatin-based chemotherapy in patients with nasopharyngeal carcinoma treated with standard radiotherapy", Radiother Oncol, 104, pp.279~285 (2012)
- Li XY, "Deintensified chemoradiotherapy for pretreatment Epstein-Barr virus DNA-selected low-risk locoregionally advanced nasopharyngeal carcinoma : a phase II randomized noninferiority trial", J Clin Oncol, 40, pp.1163~1173 (2022)
- Liu GY, "Effect of capecitabine maintenance therapy plus best supportive care vs best supportive care alone on progression-free survival among patients with newly diagnosed metastatic nasopharyngeal carcinoma who had received induction chemotherapy : a phase 3 randomized clinical trial", JAMA Oncol, 8, pp.553~561 (2022)
- Kang Y, "Advances in targeted therapy mainly based on signal pathways for nasopharyngeal carcinoma", Signal Transduct Target Ther, 5, pp.245~ (2020)
- Fang W, "Camrelizumab(SHR-1210)alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma : results from two single-arm, phase 1 trials", Lancet Oncol, 19, pp.1338~1350 (2018)
- Adkins DR, "Clinical trial data of Anti-PD-1", PDL1therapy for recurrent or metastatic nasopharyngeal carcinoma : a review, 2022, pp.109, 102428~